Products

AIxMed Computational Cytology
AIxMed
Lab & Diagnostics
AIxMed uses quantitative and qualitative data from its AI-powered computational cytology platform to enhance cytology insights, improve workflows, and transform cancer diagnosis and monitoring.

See all 1 product →

About AIxMed

AIxMed is a healthcare AI company dedicated to transforming cancer diagnosis and monitoring through its computational cytology platform. The company’s core mission is to digitize 3D cytology samples rapidly and extract clinical insights to improve patient care. Their flagship application, AIxURO™, is designed to assist in bladder cancer diagnosis using The Paris System for Reporting Urinary Cytology (TPS).

For physicians, AIxMed’s technology offers an AI-powered platform that aims to enhance cytology insights, improve workflows, and elevate the quality of patient care in the fight against cancer. AIxURO™ specifically supports the analysis of non-invasive urine cytology specimens, with the goal of improving diagnostic accuracy and workflow efficiency in bladder cancer assessment. It identifies suspicious and atypical cells from urine samples, providing quantitative and qualitative data based on The Paris System (TPS). This can potentially reduce the need for invasive procedures like cystoscopies, improve patient compliance, and contribute to more cost-effective healthcare. AIxMed emphasizes that AI in medicine is an assistant, not a replacement, and clinical judgment remains in human hands. The platform also aims to bring consistency, structure, and efficiency to cytology review workflows.

Focus Areas

AI-powered digital cytology computational pathology bladder cancer diagnosis cancer monitoring medical imaging computer vision oncology diagnostics cytology analysis pathology workflow

Business Intelligence

TechnologyAI-powered computational cytology platform, cloud-native, AI-driven digital pathology ecosystem, Z-plane scanning technology

What Physicians Need to Know

Specialization
AIxMed specializes in AI-powered digital cytology, computational pathology, and oncology diagnostics, with a primary focus on bladder cancer diagnosis and monitoring through their AIxUROu2122 platform. They are expanding into thyroid, cervical, and lung cancer applications.
Key Differentiators
AIxMed's key differentiators include their smart computational cytology platform that digitizes 3D cytology samples and extracts clinical insights rapidly. Their AIxUROu2122 solution specifically assists in the analysis of non-invasive urine cytology specimens, aiming to improve diagnostic accuracy and workflow efficiency in bladder cancer assessment by identifying suspicious and atypical cells using The Paris System (TPS) for Reporting Urinary Cytology.
Technology Stack
AIxMed leverages advanced AI and deep learning computer vision technology for cytological slide analysis. Their platform supports efficient evaluation of atypical and suspicious cells, offering features like AI-powered analysis trained on thousands of slides, identification and ranking of cells of interest, an Abnormal Cell Gallery for visual assessment, comprehensive whole-slide image analysis, detailed slide-level statistics, and in-depth cell-by-cell morphological data review. The AIxUROu2122 solution is compatible with various slide imaging systems and Papanicolaou stained slide preparation methods (Cytospin, SurePath, ThinPrep, Direct). It supports SVS, NDPI, MRXS, and selected TIF/DICOM files, and accepts TIFF, SVS, and JPG image formats.
Physician Tip

For physicians, AIxMed's solutions, particularly AIxUROu2122, offer automated prioritization, standardized data, and structured assisted workflows for cytology review, which can significantly reduce the time needed for diagnosis and enhance accuracy and speed in detecting cancerous cells. This AI-assisted approach can help triage cases, improve quality control, and make work more efficient. The technology is designed to support clinical decision-making, potentially reducing the frequency of invasive procedures like cystoscopies, enhancing patient compliance, and contributing to more cost-effective healthcare. AIxMed emphasizes that AI in medicine is an assistant, not a replacement, ensuring clinical judgment remains in human hands while boosting accuracy.

AIxMed's AIxUROu2122 is designed for seamless integration into existing laboratory environments and digital pathology infrastructures. They have established partnerships with leading digital pathology providers like Lumea, integrating AIxUROu2122 into Lumea's FDA-cleared digital pathology platform, which is utilized by a significant portion of the U.S. urology market. AIxMed also collaborates with diagnostic laboratories such as PathNet and Biopticka Laboratou0159 to integrate their technology into their workflows and Laboratory Information Systems (LIS). The platform is built for compatibility across various digital pathology environments.

Products by AIxMed

1 product in the directory

AIxMed Computational Cytology
AIxMed
Lab & Diagnostics
AIxMed uses quantitative and qualitative data from its AI-powered computational cytology platform to enhance cytology insights, improve workflows, and transform cancer diagnosis and monitoring.

Videos

News, demos, and interviews about AIxMed.

Loading videos...

Videos load interactively. If none appear, search YouTube for AIxMed →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

AIxMed offers a suite of AI-powered solutions designed for digital cytology and computational pathology, including tools for automated bladder cancer diagnosis and cancer monitoring. Our products are built to integrate seamlessly with existing laboratory information systems (LIS) and digital slide scanners, aiming to enhance efficiency and accuracy in your current pathology workflow.
AIxMed prioritizes the accuracy and reliability of its AI algorithms through rigorous validation processes using extensive datasets of medical images. Our solutions for oncology diagnostics, including bladder cancer diagnosis and cancer monitoring, are developed with a strong focus on clinical utility and are continuously refined based on real-world performance data and expert pathologist feedback.
AIxMed is committed to achieving and maintaining the highest standards of regulatory compliance for all its medical imaging and computer vision technologies used in oncology diagnostics. We are actively pursuing FDA clearance and CE Mark certification for our key products to ensure they meet the necessary safety and efficacy requirements for clinical use.
AIxMed offers flexible pricing models for our cytology analysis and pathology workflow solutions, which can be tailored to the specific needs and scale of your institution. Our packages typically include comprehensive technical support, regular software updates, and dedicated customer service to ensure optimal performance and user satisfaction.
AIxMed actively seeks partnerships with leading healthcare providers, research institutions, and technology innovators to advance the field of AI-powered oncology diagnostics. We are a well-funded company with a clear long-term vision to be a leader in digital cytology and computational pathology, continuously investing in R&D to bring cutting-edge solutions to the healthcare market.

Related Companies

LabSense AI (labsense.ai) is an AI-powered medical lab result interpreter designed to democratize medical literacy globally. The platform aims to help patients understand their lab results in plain language, regardless of their education level or location. It processes lab reports (PDF or photo uploads) and provides explanations for over 86 lab tests, including blood count, […]

OptraSCAN is a California-based digital pathology company that provides high-throughput scanners, AI-powered diagnostics, and enterprise image management solutions for modern pathology labs. OptraSCAN’s AI solutions are purpose-built for various pathology challenges, including HistoSiA™ for histology (e.g., breast cancer IHC biomarker analysis), CytoSiA™ for cytology (e.g., cervical cancer screening), and BactoSiA™ for bacteriology (e.g., TB detection […]

NeuraMetrix is a Software as a Medical Device (SaMD) company that has developed a novel digital biomarker for the detection and monitoring of neurological diseases and psychiatric disorders. The company’s core technology, NeuraMetrix Typing Cadence (TC), passively measures typing inconsistency during normal computer use. This inconsistency serves as a highly accurate indicator of cognitive and […]

Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]

Triomics is an oncology AI company dedicated to transforming how cancer centers manage complex clinical information. The company’s platform utilizes AI agents to meticulously read and interpret comprehensive longitudinal patient records, converting unstructured clinical data—such as notes, pathology reports, imaging results, and genomic panels—into structured, verifiable outputs. This process significantly reduces the manual burden on […]

Cercare Medical is an AI-powered healthcare company specializing in advanced perfusion imaging solutions for neurological diseases. Their software, the Cercare Medical Neurosuite, processes CT, CBCT, and MRI data to provide detailed insights into brain health. This technology goes beyond traditional perfusion imaging by integrating proprietary biomarkers that measure not only blood flow but also oxygenation, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.